© 2000 American Heart Association, Inc.
Molecular Medicine |
Vasodilator-Stimulated Phosphoprotein Serine 239 Phosphorylation as a Sensitive Monitor of Defective Nitric Oxide/cGMP Signaling and Endothelial Dysfunction
From the Abteilung für Kardiologie (M.O., H.M., N.H., A.W., M.B., M.S., T.M., T.M.), Universitäts-Krankenhaus Eppendorf, University of Hamburg, Hamburg; and Department of Clinical Biochemistry and Pathobiochemistry (A.S., U.W.), University of Würzburg, Germany
Correspondence to Thomas Münzel, MD, Abteilung für Kardiologie, Universitäts-Krankenhaus Eppendorf, Martinistr. 52, D-20246 Hamburg. E-mail muenzel{at}uke.uni-hamburg.de
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract—Studies with cGMP-dependent protein kinase I (cGK-I)-deficient human cells and mice demonstrated that cGK-I ablation completely disrupts the NO/cGMP pathway in vascular tissue, which indicates a key role of this protein kinase as a mediator of the NO/cGMP action. Analysis of the vasodilator-stimulated phosphoprotein phosphorylated at serine 239 (P-VASP) is a useful tool to monitor cGK-I activation in platelets and cultured endothelial and smooth muscle cells. Therefore, we investigated whether endothelial dysfunction and/or vascular NO bioavailability is reflected by decreased vessel wall P-VASP and whether improvement of endothelial dysfunction restores this P-VASP. Incubation of aortic tissue from New Zealand White Rabbits with the NOS inhibitor NG-nitro-Ld-arginine and endothelial removal strikingly reduced P-VASP. Oxidative stress induced by inhibition of CuZn superoxide dismutase increased superoxide and decreased P-VASP. Endothelial dysfunction in hyperlipidemic Watanabe rabbits (WHHL) was associated with increased vascular superoxide and with decreased P-VASP. Treatment of WHHL with AT1 receptor blockade improved endothelial dysfunction, reduced vascular superoxide, increased vascular NO bioavailability, and increased P-VASP. Therefore, the level of vessel P-VASP closely follows changes in endothelial function and vascular oxidative stress. P-VASP is suggested to represent a novel biochemical marker for monitoring the NO-stimulated sGC/cGK-I pathway and endothelial integrity in vascular tissue.
Key Words: cGMP-dependent kinase • VASP • nitric oxide • hyperlipidemia • AT1 receptor blockade
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The endothelium-derived relaxing factor, identified as NO or a closely related compound, induces vasorelaxation by activating the target enzyme soluble guanylyl cyclase (sGC) and by increasing tissue levels of the second messenger cGMP.1 Cyclic GMP in turn activates cGMP-dependent protein kinase types I and II (cGK-I and -II) of which cGK-I is highly expressed in vascular smooth muscle cell levels.2 3 4 cGK-I has mediated NO/cGMP-caused vasorelaxation, which involves phosphorylation of proteins that affect myosin light chains and intracellular Ca2+ levels.2 3 4 5 Studies with cGK-I-deficient mice demonstrated a complete disruption of the NO/cGMP signaling pathway in the vascular smooth muscle.6 Therefore, the activity and/or expression of cGK-I critically modulate NO-induced vasorelaxation. Recently, Smolenski and colleagues7 8 provided evidence that analysis of the phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at serine 239 (P-VASP) is a useful biomonitor of cGK activity and therefore NO effects in intact cells such as platelets and cultured endothelial and smooth muscle cells. Whether this is also applicable to intact vascular tissue must still be established.
Depressed vasodilation to endothelium-dependent vasodilators such as acetylcholine and to authentic NO is a hallmark of early stages of atherosclerosis.9 The mechanisms underlying endothelial dysfunction are likely to be multifactorial but seem to be, at least in part, secondary to increased NO degradation caused by activation of superoxide-producing enzymes,10 such as the xanthine oxidase,11 and a NADH-driven oxidase.12 Pritchard et al13 demonstrated that incubation of cultured endothelial cells with native LDL increased vascular superoxide production, a phenomenon that was blocked by administration of the NOS inhibitor NG-nitro-Ld-arginine methyl ester. These findings indicate that a NOS in an uncoupled state may also contribute to vascular superoxide production in the setting of hyperlipidemia. In vivo studies with animals and patients have shown that chronic AT1 receptor blockade improves endothelial function,12 14 reduces plaque formation,12 15 16 and vascular superoxide production.12 However, it remains to be established whether prevention of NOS uncoupling by AT1 receptor blocker treatment contributes to these beneficial effects.
On the basis of these considerations, the present study was designed to (1) characterize the influence of endothelium, endothelium-derived NO and superoxide on cGK-I, and P-VASP in the vasculature of rabbits; (2) test whether NOS uncoupling and impairment occurs in the NO/cGMP/cGK-I/P-VASP pathway in the setting of hypercholesterolemia; (3) test whether treatment of hypercholesterolemic animals with the AT-1 receptor blocker irbesartan improves vascular NO bioavailability and simultaneously affects P-VASP.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Animals and Protocol
Twenty-five New Zealand White rabbits (NZWR) and 25 hyperlipidemic Watanabe rabbits (WHHL) were studied. Ten of each group received concomitant treatment with the AT1 receptor antagonist irbesartan, which was mixed in the diet to achieve a daily dose of 10 mg · kg–1 · d–1.
Vessel Preparation and Organ Chamber
Studies
Aortic rings were suspended in organ chambers as
described previously.17
Vasodilator responses were determined after preconstriction with
phenylephrine to 50% to 70% of maximal (KCl-induced) tone.
Vasoconstrictor responses to angiotensin II were expressed as percent
of a maximal KCl response (80 mmol/L).
Estimation of Vascular Superoxide
Production
Vascular
O2·- was
estimated using lucigenin-derived chemiluminescence (LDCL; lucigenin
concentration, 5 µmol/L) as described
previously.18 To address the
influence of endothelial (NOS III-derived) NO and NOS-mediated
superoxide production on vascular LDCL, vessels were incubated with
NG-nitro-Ld-arginine
(L-NNA, 1 mmol/L)18 for 30
minutes as described.19 The
specificity for low-dose lucigenin for detecting superoxide has been
validated recently by the demonstration of a good correlation between
lucigenin chemiluminescence and SOD-inhibitable ferricytochrome C
reduction.20
Detection of cGK-I and VASP Expression and
P-VASP
Aortic tissue from control and hyperlipidemic WHHL
with and without irbesartan treatment was frozen and homogenized in
liquid nitrogen. The pulverized tissue was vortexed with ice-cold
homogenization buffer and centrifuged at
3000g for 5 minutes to remove
insoluble material. SDS-PAGE electrophoresis and electroblotting were
performed. The membrane was then divided horizontally at 65 kDa. For
the upper part, immunoblotting was performed with a polyclonal antibody
against cGK-I,21 and for the
lower part, mouse monoclonal P-VASP phosphoserine 239 antibodies
(16C2)8 were used. A second
blot was used to detect VASP expression by using a monoclonal antibody
against VASP (IE273).22
Immunodetections were accomplished with anti–rabbit/mouse secondary
antibodies. All bands (VASP, P-VASP, and cGK-I) were standardized
against ß-tubulin. The intensity of the P-VASP/VASP/cGK-I bands in
the treated samples was expressed as percent of the P-VASP/VASP/cGK-I
bands in the control samples. Then, all VASP serine 239 phosphorylation
data are expressed as P-VASP/VASP ratio. This ratio indicates the
extent of VASP serine 239 phosphorylation in the tissue extract
examined and corrects for variable VASP expression levels and
recoveries caused by the experimental procedures. As positive controls
for cGK-I, we used 10 ng recombinant cGK-I. As a positive control for
P-VASP, we used 1 µg protein of SNP-stimulated human
platelets.
In separate experiments, the effects of endothelial removal, inhibition of NOS, and the effects of oxidative stress on P-VASP were studied. The endothelium was removed by exposing the vessel lumen to collagenase (0.1% for 10 minutes at 37°C). To inhibit NOS, aortic rings of NZWR were incubated for 30 minutes with the NOS inhibitor NG-nitro-Ld-arginine (L-NNA, 3 mmol/L). To induce oxidative stress we inhibited CuZn SOD by incubating vessels with diethyldithiocarbamate (DETC) as described recently.23
Electron Spin Resonance Studies: Detection of
Vascular Nitric Oxide
Concentrations of NO in rabbit aorta were assayed
using ESR spectroscopy and the spin-trap iron
(II)-proline-dithiocarbamate [Fe(PrTC)2] which
has been shown to trap NO with high efficacy by forming an
ESR-detectable paramagnetic complex
Fe(NO)(PrTC)2.19
Materials
Proline dithiocarbamate was obtained from Alexis
(Grünberg, Germany). All chemicals were purchased from Sigma Chemical
(Deisenhofen, Germany).
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Effects of Endothelial Removal, L-NNA, DETC, and Hyperlipidemia on P-VASP, Total VASP and cGK-I, and Vascular Superoxide Production
In control vessels, endothelial removal markedly reduced P-VASP and to a lesser extent total VASP without altering cGK-I (Figure 1
). All phosphorylation data are subsequently
reported as P-VASP/VASP ratios, which corrects for variable VASP
recoveries and expression levels. Inhibition of NOS by L-NNA reduced
P-VASP
(Figure 1) without altering total VASP and cGK-I, which
results in an L-NNA-caused reduction of the P-VASP/VASP ratio.
Inhibition of CuZn SOD with DETC increased vascular superoxide and
simultaneously reduced P-VASP without altering total VASP and cGK-I
(Figure 2). In hyperlipidemic WHHL, increased vascular
superoxide levels were associated with reduced P-VASP, whereas total
VASP (as detected with the IE273 antibody) was reduced only moderately
(Figure 2). Incubation of vessels from NZWR with sodium
nitroprusside (SNP, 10–5 M) for 30 minutes
increased P-VASP. Likewise, incubation of vessels from WHHL with SNP
increased P-VASP to a similar degree
(Figure 3).
|
|
|
Effects of AT1 Receptor
Blockade on Vasodilator Responses to Acetylcholine and
Nitroglycerin
In hyperlipidemic Watanabe rabbits, the sensitivity to
endothelium-dependent (ACh) and endothelium-independent (NTG)
relaxation was reduced significantly
(Table 1). AT1 receptor blockade for
8 weeks had no effect on the ACh and NTG dose-response relationship of
control animals but significantly improved it in WHHL
(Table 1), compatible with an improved sensitivity to
NO-mediated vasodilation. AT1 receptor blockade
for 8 weeks inhibited sensitivity and potency of angiotensin II in
vessels from control and from hypercholesterolemic animals, compatible
with a sufficient blockade of the AT1 receptor
(Table 2).
|
|
Effects of AT1 Receptor
Blockade on Vascular Superoxide and NOS III Uncoupling in
Hyperlipidemic Watanabe Rabbits
Hyperlipidemia led to a significant increase in LDCL
compared with controls
(Figure 4). Treatment of control animals with irbesartan had
a slight but significant effect on LDCL. AT1
receptor blockade markedly reduced vascular superoxide levels in
hyperlipidemic WHHL. Incubation of control vessels with the NOS
inhibitor L-NNA increased the LDCL signals but paradoxically decreased
it in vessels from hyperlipidemic animals. Incubation of vessels from
hyperlipidemic animals treated with both irbesartan and L-NNA increased
LDCL comparable with control vessels.
|
P<0.05 vs WHHL without
irbesartan
treatment.
Effects of AT1 Receptor
Blockade on P-VASP in Control and Hyperlipidemic WHHL
The effects of AT1 receptor
blockade on cGK-I and VASP expression as well as on P-VASP are depicted
in
Figure 5 (original blots and quantitative densitometry).
Treatment of control animals with irbesartan had no effect on cGK-I,
VASP expression, and P-VASP. In hyperlipidemic animals we found no
significant decrease in cGK-I and a minor decrease of total VASP, but
P-VASP was strikingly reduced. Treatment of hyperlipidemic animals with
irbesartan significantly increased P-VASP.
|
Effects of AT1 Receptor
Blockade on Vascular NO Bioavailability of Hyperlipidemic WHHL
The effects of irbesartan treatment on vascular NO
bioavailability in vascular tissue as assessed with ESR spectroscopy
are depicted in
Figure 6. The representative ESR recording of the signal of
the iron-nitrosyl dithiocarbamate complex
Fe(NO)(PrTC)2 was strikingly reduced in vessels
from hyperlipidemic WHHL animals as compared with spectra obtained from
vessels from WHHL treated with
irbesartan.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
P-VASP as Indicator of Vessel Wall Integrity and cGK-I Activity
The present study demonstrates that the level of vasodilator-stimulated phosphoprotein phosphorylated at serine 239 (P-VASP) in the rabbit aortic vessel wall is an indicator of both cGK-I activity and endothelium integrity under physiological and pathophysiological conditions. It is now well established that the NO-cGMP pathway is a key regulator of vascular tone and that cGK-I mediates many of these NO/cGMP effects. Studies with cGK-I-deficient human cells and mice demonstrated that cGK-I ablation disrupts the NO/cGMP pathway in vascular cells and tissues.3 6 Gene-targeted loss of murine cGK-I abolished NO/cGMP-dependent relaxation of smooth muscle resulting in severe vascular and intestinal dysfunctions, whereas cAMP-mediated smooth muscle relaxation was not impaired.5 6 These recent developments highlight the importance of assessing cGK expression and/or cGK activity in the presence of endothelial dysfunction. However, cGMP-independent NO effects in vascular tissues exist which are not addressed by our present study.
This study shows that vascular wall cGK-I activity can be
estimated by the analysis of VASP phosphorylation. VASP is a
well-characterized substrate for both cGK and cAMP-dependent protein
kinase (cAK) in platelets, vascular endothelial and smooth muscle
cells, and many other cell types and
tissues.24 25 26 27
Functionally, VASP regulates microfilaments and enhances spatially
confined actin
polymerization.22 28
In platelets, VASP and VASP phosphorylation have recently been
demonstrated to be involved in the inhibition of agonist-induced
platelet aggregation and, in particular, integrin
Iibß3
activation.29 30
In smooth muscle function and relaxation, however, the precise role of
VASP and VASP phosphorylation remains to be
established.29 30
In platelets and many primary and cultured cell types, activation of
cAK and cGK can be monitored by antibodies, which are specific for the
distinct VASP phosphorylation sites (serine 157, serine 239, and
threonine 278,8 22
other data not shown). Although all 3 sites can be phosphorylated by
both protein kinases, serine 157 and serine 239 are the preferred
phosphorylation sites for cAK or cGK,
respectively.7 8 22 31
Studies with cGK-I-deficient cells established that the
NO/cGMP-mediated VASP phosphorylation is mediated by
cGK-I.3 26 It
remains to be established, however, whether a similar approach can be
used with intact vascular tissue.
Here, we found that removal of the rabbit aorta endothelium strikingly reduced P-VASP (detected by the monoclonal antibody 16C2) to 5±1% and moderately reduced (down to 61±5%) total vessel VASP (detected by the monoclonal antibody IE273), which collectively also resulted in a substantially reduced P-VASP/VASP-ratio (down to 15±7%). The cGK-I content did not change significantly. Although cGK-I is clearly expressed in endothelial cells,3 26 our present data indicate that the endothelium contributes only a minor amount to the overall content of the rabbit aortic vessel cGK-I. In contrast, the endothelial layer and medial layer of the rabbit aorta appear to contribute about one third and two thirds, respectively, of the total content of vessel wall VASP. These data agree with previous immunohistochemical studies, which demonstrated high levels of VASP in medial, intimal, and neointimal layers of the rat carotid artery.27 The data also show that the presence of P-VASP in this vessel almost exclusively depends on the presence of the endothelium. Incubation of aortic pieces with the NOS inhibitor L-NNA decreased P-VASP to 35±4% indicating that endothelium-derived NO is a major contributor to VASP phosphorylation in vascular tissue. The half-life of NO and therefore its biological activity is determined decisively by oxygen-derived free radicals such as superoxide.32 To analyze the effects of oxidative stress on P-VASP, we incubated vascular tissue in vitro with the inhibitor of the superoxide-scavenging enzyme CuZn-SOD DETC. Incubation of vascular tissue with DETC markedly increases steady-state superoxide levels and simultaneously causes endothelial dysfunction.23 Increased superoxide inactivates NO derived from endothelial cells via formation of peroxynitrite, which has been much less potent in stimulating the downstream target soluble guanylyl cyclase.33
Accordingly, we found that P-VASP in DETC incubated vessels
was strikingly reduced, whereas total VASP content and cGK-I were not
modified. Similar changes were observed in an in vivo model of
oxidative stress such as hypercholesterolemia. In hyperlipidemic WHHL
we established endothelial dysfunction, increased vascular superoxide
production, and accordingly decreased P-VASP production. Total VASP
(determined with the IE273 antibody) did not decrease significantly
indicating that decreased NO/cGMP signaling (as measured by the level
of NO/cGMP-increased P-VASP) rather than decreased expression of the
cGK-I substrate accounts for this phenomenon. Incubation of control and
tissue from hyperlipidemic animals with the NO donor SNP revealed
similar increases in the phosphorylation of VASP
(Figure 3
), which demonstrates that the cGMP signaling
pathway downstream of the soluble guanylyl cyclase per se is not
impaired. These findings further indicate that NO derived from
endothelial cells or NO left after interactions with superoxide
(vascular NO bioavailability) is closely monitored by the degree of
VASP phosphorylation (P-VASP). In addition, endothelial dysfunction in
hyperlipidemic animals is not likely to be secondary to decreases in
the expression of either cGK-I or its substrate VASP. cGK-I and VASP
are also well expressed in neointimal cells of the injured rat carotid
artery.27
Evidence for NOS Uncoupling in
Hyperlipidemia
Our current findings are supported by previous
observations showing that hypercholesterolemia is associated with
endothelial dysfunction and increased vascular superoxide
production.12 In
hyperlipidemic Watanabe rabbits, vascular superoxide was increased
about 2-fold compared with controls. Treatment of hyperlipidemic WHHL
with an AT1 receptor blocker improves
endothelial dysfunction and simultaneously reduces vascular superoxide
production.12
It has become clear from studies that both NOS I and NOS III may become "uncoupled" in the absence of Ld-arginine or tetrahydrobiopterin. In such uncoupled state, electrons flowing from the reductase domain to the oxygenase domain are diverted to molecular oxygen rather than to Ld-arginine34 35 resulting in production of superoxide rather than NO. Recent in vitro studies proposed that oxidized LDL in particular is able to decrease endothelial Ld-arginine uptake ultimately leading to both local depletion of Ld-arginine and NOS III uncoupling.36 Hypercholesterolemia also has increased vascular formation of superoxide10 leading to increased formation of the NO/superoxide reaction product peroxynitrite.37 Peroxynitrite in turn rapidly oxidizes the active NOS cofactor tetrahydrobiopterin to cofactor inactive molecules such as dihydrobiopterin,38 leading to NOS III uncoupling.
With the present studies we provide evidence that an uncoupled NOS III is at least partially involved in the increased superoxide production seen in vessels from hyperlipidemic WHHL. When control aortas were exposed to the NOS inhibitor L-NNA, a significant increase in the LDCL signal was observed. This indicates that the amount of NO formed in normal vascular endothelium under basal conditions is sufficiently high to compete for the reaction of superoxide with lucigenin.18 In contrast, incubation of aortic tissue from WHHL with L-NNA decreased rather than increased steady-state vascular superoxide levels identifying NOS III as a significant superoxide source. These data obtained from in vivo cholesterol-fed hyperlipidemic animals coincide exactly with recent in vitro observations. In these experiments, Pritchard et al13 demonstrated that L-NAME (the methyl ester of L-NNA) increased steady-state superoxide levels in cultured endothelial cells. After incubation of the endothelial cells with native LDL, superoxide levels increased markedly, a phenomenon that was largely blocked by L-NAME identifying NOS III as an important superoxide source. We cannot entirely exclude, however, that the inhibitory effects of L-NNA on superoxide levels in hyperlipidemia are secondary to some stimulatory NO effects on vascular oxidases.
AT1 Receptor Blockade
Prevents NOS Uncoupling and Increases P-VASP
Next we studied the effects of
AT1 receptor blockade with irbesartan on
endothelial function, vascular superoxide, NOS-mediated superoxide
production, vascular NO/cGMP signaling as measured by the content of
P-VASP. Treatment of hyperlipidemic animals with the
AT1 receptor blocker irbesartan significantly
improved endothelial function without altering plasma cholesterol
levels (data not shown). These data agree with our previous
observations that blockade of the AT1 receptor
beneficially influences vascular function in hyperlipidemic
animals12 and patients with
coronary artery disease.14
Irbesartan significantly improved endothelial dysfunction of
hyperlipidemic WHHL and reduced vascular steady-state superoxide
levels. Incubation of vessels from irbesartan-treated hyperlipidemic
animals with the NOS inhibitor increased vascular superoxide rather
than decreased it (compatible with changes observed in controls), which
indicates that AT1 receptor blockade may reduce
oxidative stress at least in part by preventing NOS III uncoupling (see
Figure 4). Hypercholesterolemia has been associated with
increases in vascular AT1 receptor
expression12 39
and increased formation of angiotensin II in vascular
tissue.40 Acute incubation
of vessels with angiotensin II stimulates peroxynitrite
formation.41 Taking into
account the above-mentioned mechanisms of NOS uncoupling, we therefore
hypothesize that chronic AT1 receptor blockade
may reduce NOS III-mediated superoxide production by reducing vascular
peroxynitrite formation and therefore less oxidation of the
redox-sensitive NOS III cofactor tetrahydrobiopterin. The reduction of
oxidative stress within vascular tissue [eg, also via inhibition of
the NAD(P)H oxidase] decreases oxidation of LDL, which in turn may
favorably influence intracellular
Ld-arginine
availability.36
The inhibition of superoxide production in vessels from WHHL
treated with irbesartan led to a significant increase in vascular NO
bioavailability as assessed by ESR measurements. Accordingly, we found
that P-VASP, which was markedly depressed in WHHL, was significantly
enhanced after concomitant AT1 receptor blocker
treatment
(Figure 6).
Conclusions
The present studies demonstrate that the level of
P-VASP in the rabbit aorta is strikingly regulated by the vascular
NO/cGMP signaling pathway. Endothelial removal and inhibition of NOS or
increases in oxidative stress in vitro and in vivo markedly decreases
the VASP phosphorylation at the cGK-preferred phosphorylation site
serine 239. Treatment of hypercholesterolemic animals with the
AT1 receptor blocker irbesartan improved
endothelial dysfunction, reduced vascular superoxide production,
increased vascular NO bioavailability, and accordingly increased
P-VASP. Therefore, P-VASP seems to be a new biochemical marker capable
of monitoring the NO/sGC/cGK-I pathway in rabbit aorta, which presents
a major aspect of NO bioavailability in vascular tissues. Considering
the established inhibitory role of VASP and VASP phosphorylation on
platelet activation, VASP phosphorylation may also contribute to the
vasoprotective effects of the NO/cGMP pathway in the healthy and
diseased vessel
wall.
|
Acknowledgments |
|---|
This work was supported by the Deutsche Forschungsgemeinschaft (Mu, 1079/2-2; SFB 355) and in part by a vascular biology grant from Bristol Myers Squibb.
Received June 27, 2000; revision received September 26, 2000; accepted September 27, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Murad F, Waldman S, Molina C, Bennett B, Leitman D. Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation. Progr Clin Biol Res. 1987;249:65–76.[Medline] [Order article via Infotrieve]
2. Lincoln TM, Pryzwansky KB, Cornwell TL, Wyatt TA, MacMillan LA. Cyclic-GMP-dependent protein kinase in smooth muscle and neutrophils. Adv Second Messenger Phosphoprot Res. 1993;28:121–132.[Medline] [Order article via Infotrieve]
3. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci. 1997;22:307–312.[Medline] [Order article via Infotrieve]
4.
Surks HK, Mochizuki
N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME.
Regulation of myosin phosphatase by a specific interaction with
cGMP-dependent protein kinase I.
Science. 1999;286:1583–1587.
5. Hofmann F, Ammendola A, Schlossmann J. Rising behind NO: cGMP-dependent protein kinases. J Cell Sci. 2000;113:1671–1676.[Abstract]
6. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Himeiss C, Wang GX, Korth M, Aszodi A, Andersson KE, Krombach F, Mayerhofer A, Ruth P, Fassler R, Hofmann F. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998;17:3045–3051.[Medline] [Order article via Infotrieve]
7. Smolenski A, Burkhardt AM, Eigenthaler M, Butt E, Gambaryan S, Lohmann SM, Walter U. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol. 1998;358:134–139.[Medline] [Order article via Infotrieve]
8.
Smolenski A,
Bachmann C, Reinhard K, Honig-Liedl P, Jarchau T, Hoschuetzky H, Walter
U. Analysis and regulation of vasodilator-stimulated phosphoprotein
serine 239 phosphorylation in vitro and in intact cells using a
phosphospecific monoclonal antibody.
J Biol Chem. 1998;273:20029–20035.
9. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995;38:105–128.[Medline] [Order article via Infotrieve]
10. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–2551.
11.
White CR,
Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks
DA, Tarpey MM, Freeman BA. Circulating plasma xanthine oxidase
contributes to vascular dysfunction in hypercholesterolemic rabbits.
Proc Natl Acad Sci
U S A. 1996;93:8745–8749.
12.
Warnholtz A,
Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T,
Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T.
Increased NADH-oxidase-mediated superoxide production in the early
stages of atherosclerosis: evidence for involvement of the renin-
angiotensin system.
Circulation. 1999;99:2027–2033.
13.
Pritchard KA Jr,
Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman
MB. Native low-density lipoprotein increases endothelial cell nitric
oxide synthase generation of superoxide anion.
Circ Res. 1995;77:510–518.
14.
Prasad A,
Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA,
Ellahham S, Quyyumi AA. Acute and chronic angiotensin-1 receptor
antagonism reverses endothelial dysfunction in atherosclerosis.
Circulation. 2000;101:2349–2354.
15.
Strawn WB,
Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early
atherogenesis by losartan in monkeys with diet-induced
hypercholesterolemia.
Circulation. 2000;101:1586–1593.
16. Keidar S, Attias J, Smith J, Breslow JL, Hayek T.. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622–625.[Medline] [Order article via Infotrieve]
17. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187–194.
18. Skatchkov MP, Sperling D, Hink U, Mulsch A, Harrison DG, Sindermann I, Meinertz T, Munzel T. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun. 1999;254:319–324.[Medline] [Order article via Infotrieve]
19. Munzel T, Li H, Mollnau H, Hink U, Matheis E, Hartmann M, Oelze M, Skatchkov M, Warnholtz A, Duncker L, Meinertz T, Forstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res. 2000;86:E7–E12.
20. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86:E85–90.
21. Markert T, Vaandrager AB, Gambaryan S, Pohler D, Hausler C, Walter U, De Jonge HR, Jarchau T, Lohmann SM. Endogenous expression of type II cGMP-dependent protein kinase mRNA and protein in rat intestine. Implications for cystic fibrosis transmembrane conductance regulator. J Clin Invest. 1995;96:822–830.
22. Reinhard M, Jarchau T, Reinhard K, Walter U. VASP. In: Kreis T, Vale R, eds.Guidebook to the Cytoskeletal and Motor Proteins. New York, NY: Oxford University Press; 1999:168–171.
23. Munzel T, Hink U, Yigit H, Macharzina R, Harrison DG, Mulsch A. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. Br J Pharmacol. 1999;127:1224–1230.[Medline] [Order article via Infotrieve]
24.
Halbrugge M,
Friedrich C, Eigenthaler M, Schanzenbacher P, Walter U. Stoichiometric
and reversible phosphorylation of a 46-kDa protein in human platelets
in response to cGMP- and cAMP-elevating vasodilators.
J Biol Chem. 1990;265:3088–3093.
25. Reinhard M, Halbrugge M, Scheer U, Wiegand C, Jockusch BM, Walter U. The 46/50 kDa phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts. EMBO J. 1992;11:2063–2070.[Medline] [Order article via Infotrieve]
26.
Draijer R,
Vaandrager AB, Nolte C, de Jonge HR, Walter U, van Hinsbergh VW.
Expression of cGMP-dependent protein kinase I and phosphorylation of
its substrate, vasodilator-stimulated phosphoprotein, in human
endothelial cells of different origin.
Circ Res. 1995;77:897–905.
27. Monks D, Lange V, Silber RE, Markert T, Walter U, Nehls V. Expression of cGMP-dependent protein kinase I and its substrate VASP in neointimal cells of the injured rat carotid artery. Eur J Clin Invest. 1998;28:416–423.[Medline] [Order article via Infotrieve]
28. Loisel TP, Boujemaa R, Pantaloni D, Carlier MF. Reconstitution of actin-based motility of Listeria and Shigella using pure proteins. Nature. 1999;401:613–616.[Medline] [Order article via Infotrieve]
29. Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson KE, Kehrel B, Offermanns S, Fassler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 1999;18:37–48.[Medline] [Order article via Infotrieve]
30.
Hauser W,
Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, Geiger J, Glazova M,
Rohde E, Horak I, Walter U, Zimmer M. Megakaryocyte hyperplasia and
enhanced agonist-induced platelet activation in vasodilator-stimulated
phosphoprotein knockout mice. Proc Natl
Acad Sci
U S A. 1999;96:8120–8125.
31. Becker EM, Schmidt P, Schramm M, Schroder H, Walter U, Hoenicka M, Gerzer R, Stasch JP. The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. J Cardiovasc Pharmacol. 2000;35:390–397.[Medline] [Order article via Infotrieve]
32. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454–456.[Medline] [Order article via Infotrieve]
33. Tarpey MM, Beckman JS, Ischiropoulos H, Gore JZ, Brock TA. Peroxynitrite stimulates vascular smooth muscle cell cyclic GMP synthesis. FEBS Lett. 1995;364:314–318.[Medline] [Order article via Infotrieve]
34.
Xia Y, Tsai AL,
Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide
synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin
regulatory process. J Biol
Chem. 1998;273:25804–25808.
35.
Vasquez-Vivar J,
Kalyanaraman B, Martasek P, Hogg N, Masters BSS, Karoui H, Tordo P,
Pritchard KA Jr. Superoxide generation by endothelial nitric oxide
synthase: the influence of cofactors. Proc
Natl Acad Sci
U S A. 1998;95:9220–9225.
36.
Vergnani L,
Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovych V,
Fellin R, Malinski T. Effect of native and oxidized low-density
lipoprotein on endothelial nitric oxide and superoxide production: key
role of Ld-arginine
availability. Circulation. 2000;101:1261–1266.
37.
White CR, Brock
TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore
J, Freeman BA, et al. Superoxide and peroxynitrite in atherosclerosis.
Proc Natl Acad Sci
U S A. 1994;91:1044–1048.
38. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun. 1999;263:681–684.[Medline] [Order article via Infotrieve]
39. Nickenig G, Bohm M. Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia. Eur J Med Res. 1997;2:285–289.[Medline] [Order article via Infotrieve]
40.
Diet F, Pratt RE,
Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of
tissue ACE in human atherosclerotic coronary artery disease.
Circulation. 1996;94:2756–2767.
41.
Pueyo ME, Arnal
JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO
and peroxynitrite in endothelial cells.
Am J Physiol. 1998;274:C214–220.
This article has been cited by other articles:
 |
|
 |
|
  A. Pautz, P. Rauschkolb, N. Schmidt, J. Art, M. Oelze, P. Wenzel, U. Forstermann, A. Daiber, and H. Kleinert Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects Physiol Genomics, July 1, 2009; 38(2): 176 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schafer, D. Fraccarollo, J. Widder, M. Eigenthaler, G. Ertl, and J. Bauersachs Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer Eur J Heart Fail, April 1, 2009; 11(4): 336 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Neppl, L. T. Lubomirov, K. Momotani, G. Pfitzer, M. Eto, and A. V. Somlyo Thromboxane A2-induced Bi-directional Regulation of Cerebral Arterial Tone J. Biol. Chem., March 6, 2009; 284(10): 6348 - 6360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Hughes, O. Wirth, K. Krajnak, R. Miller, S. Flavahan, D. E. Berkowitz, D. Welcome, and N. A. Flavahan Increased Oxidant Activity Mediates Vascular Dysfunction in Vibration Injury J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 223 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, M. Hortmann, A. Daiber, M. Oelze, M. A. Ostad, P. M. Schwarz, H. Xu, N. Xia, A. L. Kleschyov, C. Mang, et al. Cyclooxygenase 2-Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs Induce Oxidative Stress by Up-Regulating Vascular NADPH Oxidases J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 745 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Imanishi, H. Tsujioka, H. Ikejima, A. Kuroi, S. Takarada, H. Kitabata, T. Tanimoto, Y. Muragaki, S. Mochizuki, M. Goto, et al. Renin Inhibitor Aliskiren Improves Impaired Nitric Oxide Bioavailability and Protects Against Atherosclerotic Changes Hypertension, September 1, 2008; 52(3): 563 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fraccarollo, J. D. Widder, P. Galuppo, T. Thum, D. Tsikas, M. Hoffmann, H. Ruetten, G. Ertl, and J. Bauersachs Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction Circulation, August 19, 2008; 118(8): 818 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Desjardins, I. Lobysheva, M. Pelat, B. Gallez, O. Feron, C. Dessy, and J.-L. Balligand Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis Cardiovasc Res, August 1, 2008; 79(3): 527 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cho, C. Park, I.-Y. Hwang, S.-B. Han, D. Schimel, D. Despres, and J. H. Kehrl Rgs5 Targeting Leads to Chronic Low Blood Pressure and a Lean Body Habitus Mol. Cell. Biol., April 15, 2008; 28(8): 2590 - 2597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Russo, P. Del Mese, G. Doronzo, L. Mattiello, M. Viretto, A. Bosia, G. Anfossi, and M. Trovati Resistance to the Nitric Oxide/Cyclic Guanosine 5'-Monophosphate/Protein Kinase G Pathway in Vascular Smooth Muscle Cells from the Obese Zucker Rat, a Classical Animal Model of Insulin Resistance: Role of Oxidative Stress Endocrinology, April 1, 2008; 149(4): 1480 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, Y. C. Levine, D. E. Golan, T. Michel, and A. J. Lin Atrial Natriuretic Peptide-initiated cGMP Pathways Regulate Vasodilator-stimulated Phosphoprotein Phosphorylation and Angiogenesis in Vascular Endothelium J. Biol. Chem., February 15, 2008; 283(7): 4439 - 4447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cheng, J.-S. Ou, H. Singh, J. R. Falck, D. Narsimhaswamy, K. A. Pritchard Jr., and M. L. Schwartzman 20-Hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1018 - H1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kirsch, B. Kemp-Harper, N. Weissmann, F. Grimminger, and H. H. H. W. Schmidt Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling FASEB J, January 1, 2008; 22(1): 30 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zhang, S. Zhuang, D. E. Casteel, D. J. Looney, G. R. Boss, and R. B. Pilz A Cysteine-rich LIM-only Protein Mediates Regulation of Smooth Muscle-specific Gene Expression by cGMP-dependent Protein Kinase J. Biol. Chem., November 16, 2007; 282(46): 33367 - 33380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Lindsay, S. Ramsey, M. Aitchison, T. Renne, and T. J. Evans Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239 J. Cell Sci., September 1, 2007; 120(17): 3011 - 3021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vermeersch, E. Buys, P. Pokreisz, G. Marsboom, F. Ichinose, P. Sips, M. Pellens, H. Gillijns, M. Swinnen, A. Graveline, et al. Soluble Guanylate Cyclase-{alpha}1 Deficiency Selectively Inhibits the Pulmonary Vasodilator Response to Nitric Oxide and Increases the Pulmonary Vascular Remodeling Response to Chronic Hypoxia Circulation, August 21, 2007; 116(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Romeo, K. S. Moulton, and A. Kazlauskas Attenuated Expression of Profilin-1 Confers Protection From Atherosclerosis in the LDL Receptor Null Mouse Circ. Res., August 17, 2007; 101(4): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Takimoto, D. Belardi, C. G. Tocchetti, S. Vahebi, G. Cormaci, E. A. Ketner, A. L. Moens, H. C. Champion, and D. A. Kass Compartmentalization of Cardiac {beta}-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 Circulation, April 24, 2007; 115(16): 2159 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Arishiro, M. Hoshiga, N. Negoro, D. Jin, S. Takai, M. Miyazaki, T. Ishihara, and T. Hanafusa Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1482 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Antl, M.-L. von Bruhl, C. Eiglsperger, M. Werner, I. Konrad, T. Kocher, M. Wilm, F. Hofmann, S. Massberg, and J. Schlossmann IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation Blood, January 15, 2007; 109(2): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Suzuki, K. Eguchi, H. Ohtsu, S. Higuchi, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Activation of Endothelial Nitric Oxide Synthase by the Angiotensin II Type 1 Receptor Endocrinology, December 1, 2006; 147(12): 5914 - 5920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Oelze, A. Daiber, R. P. Brandes, M. Hortmann, P. Wenzel, U. Hink, E. Schulz, H. Mollnau, A. von Sandersleben, A. L. Kleschyov, et al. Nebivolol Inhibits Superoxide Formation by NADPH Oxidase and Endothelial Dysfunction in Angiotensin II-Treated Rats Hypertension, October 1, 2006; 48(4): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oelze, A. Warnholtz, J. Faulhaber, P. Wenzel, A. L. Kleschyov, M. Coldewey, U. Hink, O. Pongs, I. Fleming, S. Wassmann, et al. NADPH Oxidase Accounts for Enhanced Superoxide Production and Impaired Endothelium-Dependent Smooth Muscle Relaxation in BK{beta}1-/- Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1753 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pignatelli, S. Di Santo, B. Buchetti, V. Sanguigni, A. Brunelli, and F. Violi Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment FASEB J, June 1, 2006; 20(8): 1082 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Schindler, H. Strobel, K. Schonafinger, W. Linz, M. Lohn, P. A. Martorana, H. Rutten, P. W. Schindler, A. E. Busch, M. Sohn, et al. Biochemistry and Pharmacology of Novel Anthranilic Acid Derivatives Activating Heme-Oxidized Soluble Guanylyl Cyclase Mol. Pharmacol., April 1, 2006; 69(4): 1260 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Mills, H. Tornqvist, S. D. Robinson, M. Gonzalez, K. Darnley, W. MacNee, N. A. Boon, K. Donaldson, A. Blomberg, T. Sandstrom, et al. Diesel Exhaust Inhalation Causes Vascular Dysfunction and Impaired Endogenous Fibrinolysis Circulation, December 20, 2005; 112(25): 3930 - 3936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mollnau, M. Oelze, M. August, M. Wendt, A. Daiber, E. Schulz, S. Baldus, A. L. Kleschyov, A. Materne, P. Wenzel, et al. Mechanisms of Increased Vascular Superoxide Production in an Experimental Model of Idiopathic Dilated Cardiomyopathy Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2554 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Williams, M. J. Coffey, B. Coles, S. Sanchez, J. D. Morrow, J. R. Cockcroft, M. J. Lewis, and V. B. O'Donnell In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets Blood, October 15, 2005; 106(8): 2737 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel, A. Daiber, and A. Mulsch Explaining the Phenomenon of Nitrate Tolerance Circ. Res., September 30, 2005; 97(7): 618 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Daiber, M. Oelze, S. Sulyok, M. Coldewey, E. Schulz, N. Treiber, U. Hink, A. Mulsch, K. Scharffetter-Kochanek, and T. Munzel Heterozygous Deficiency of Manganese Superoxide Dismutase in Mice (Mn-SOD+/-): A Novel Approach to Assess the Role of Oxidative Stress for the Development of Nitrate Tolerance Mol. Pharmacol., September 1, 2005; 68(3): 579 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel, A. Daiber, V. Ullrich, and A. Mulsch Vascular Consequences of Endothelial Nitric Oxide Synthase Uncoupling for the Activity and Expression of the Soluble Guanylyl Cyclase and the cGMP-Dependent Protein Kinase Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1551 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wharton, J. W. Strange, G. M. O. Moller, E. J. Growcott, X. Ren, A. P. Franklyn, S. C. Phillips, and M. R. Wilkins Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 105 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P Cooke ADMA: its role in vascular disease Vascular Medicine, July 1, 2005; 10(1_suppl): S11 - S17. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Satoh, S. Fujimoto, Y. Haruna, S. Arakawa, H. Horike, N. Komai, T. Sasaki, K. Tsujioka, H. Makino, and N. Kashihara NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1144 - F1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P Cooke ADMA: its role in vascular disease Vascular Medicine, May 1, 2005; 10(2_suppl): S11 - S17. [Abstract] [PDF]
|
|
|
|
|
|
A. Schafer, D. Fraccarollo, M. Eigenthaler, P. Tas, A. Firnschild, S. Frantz, G. Ertl, and J. Bauersachs Rosuvastatin Reduces Platelet Activation in Heart Failure: Role of NO Bioavailability Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hohenstein, L. Kasperek, D.-J. Kobelt, C. Daniel, S. Gambaryan, T. Renne, U. Walter, K. U. Amann, and C. P.M. Hugo Vasodilator-Stimulated Phosphoprotein-Deficient Mice Demonstrate Increased Platelet Activation but Improved Renal Endothelial Preservation and Regeneration in Passive Nephrotoxic Nephritis J. Am. Soc. Nephrol., April 1, 2005; 16(4): 986 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yao, N. Hiramatsu, Y. Zhu, T. Morioka, M. Takeda, T. Oite, and M. Kitamura Nitric Oxide-Mediated Regulation of Connexin43 Expression and Gap Junctional Intercellular Communication in Mesangial Cells J. Am. Soc. Nephrol., January 1, 2005; 16(1): 58 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. O. Melichar, D. Behr-Roussel, U. Zabel, L. O. Uttenthal, J. Rodrigo, A. Rupin, T. J. Verbeuren, A. Kumar H. S., and H. H. H. W. Schmidt Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis PNAS, November 23, 2004; 101(47): 16671 - 16676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schafer, N. J. Alp, S. Cai, C. A. Lygate, S. Neubauer, M. Eigenthaler, J. Bauersachs, and K. M. Channon Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1720 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schafer, F. Wiesmann, S. Neubauer, M. Eigenthaler, J. Bauersachs, and K. M. Channon Rapid Regulation of Platelet Activation In Vivo by Nitric Oxide Circulation, April 20, 2004; 109(15): 1819 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Alp and K. M. Channon Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 413 - 420. [Abstract] [Full Text]
|
|
|
|
|
|
N. J. Alp, M. A. McAteer, J. Khoo, R. P. Choudhury, and K. M. Channon Increased Endothelial Tetrahydrobiopterin Synthesis by Targeted Transgenic GTP-Cyclohydrolase I Overexpression Reduces Endothelial Dysfunction and Atherosclerosis in ApoE-Knockout Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 445 - 450. [Abstract] [Full Text]
|
|
|
|
|
|
L. Tao, H.-R. Liu, E. Gao, Z.-P. Teng, B. L. Lopez, T. A. Christopher, X.-L. Ma, I. Batinic-Haberle, R. N. Willette, E. H. Ohlstein, et al. Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist in Hypercholesterolemia Circulation, December 2, 2003; 108(22): 2805 - 2811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Hink, M. Oelze, P. Kolb, M. Bachschmid, M.-H. Zou, A. Daiber, H. Mollnau, M. August, S. Baldus, N. Tsilimingas, et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1826 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF]
|
|
|
|
|
|
J. Widder, T. Pelzer, C. von Poser-Klein, K. Hu, V. Jazbutyte, K.-H. Fritzemeier, C. Hegele-Hartung, L. Neyses, and J. Bauersachs Improvement of Endothelial Dysfunction by Selective Estrogen Receptor-{alpha} Stimulation in Ovariectomized SHR Hypertension, November 1, 2003; 42(5): 991 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kleschyov, M. Oelze, A. Daiber, Y. Huang, H. Mollnau, E. Schulz, K. Sydow, B. Fichtlscherer, A. Mulsch, and T. Munzel Does Nitric Oxide Mediate the Vasodilator Activity of Nitroglycerin? Circ. Res., October 31, 2003; 93 (9): e104 - e112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Dixon, D. R. Morgan, S. M. Hughes, L. T. McGrath, N. A. El-Sherbeeny, R. D. Plumb, A. Devine, W. Leahey, G. D. Johnston, and G. E. McVeigh Functional Consequences of Endothelial Nitric Oxide Synthase Uncoupling in Congestive Cardiac Failure Circulation, April 8, 2003; 107(13): 1725 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mollnau, E. Schulz, A. Daiber, S. Baldus, M. Oelze, M. August, M. Wendt, U. Walter, C. Geiger, R. Agrawal, et al. Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 615 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Aktas, A. Utz, P. Hoenig-Liedl, U. Walter, and J. Geiger Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human Platelets: In Vitro and In Vivo/Ex Vivo Studies Stroke, March 1, 2003; 34(3): 764 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Warnholtz, H. Mollnau, T. Heitzer, A. Kontush, T. Moller-Bertram, D. Lavall, A. Giaid, U. Beisiegel, S. L. Marklund, U. Walter, et al. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mollnau, M. Wendt, K. Szocs, B. Lassegue, E. Schulz, M. Oelze, H. Li, M. Bodenschatz, M. August, A. L. Kleschyov, et al. Effects of Angiotensin II Infusion on the Expression and Function of NAD(P)H Oxidase and Components of Nitric Oxide/cGMP Signaling Circ. Res., March 8, 2002; 90 (4): e58 - e65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ibarra-Alvarado, J. Galle, V. O. Melichar, A. Mameghani, and H. H. H. W. Schmidt Phosphorylation of Blood Vessel Vasodilator-Stimulated Phosphoprotein at Serine 239 as a Functional Biochemical Marker of Endothelial Nitric Oxide/Cyclic GMP Signaling Mol. Pharmacol., February 1, 2002; 61(2): 312 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, and T. Munzel Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease Circulation, November 27, 2001; 104(22): 2673 - 2678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel Does nitroglycerin therapy hit the endothelium? J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1102 - 1105. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bader, E. Butt, A. Palmetshofer, U. Walter, T. Jarchau, and P. Drueckesl A cGMP-Dependent Protein Kinase Assay for High Throughput Screening Based on Time-Resolved Fluorescence Resonance Energy Transfer J Biomol Screen, August 1, 2001; 6(4): 255 - 264. [Abstract] [PDF]
|
|
|
|
|
|
P. H. Ratz Regulation of ERK phosphorylation in differentiated arterial muscle of rabbits Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H114 - H123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schulz, N. Tsilimingas, R. Rinze, B. Reiter, M. Wendt, M. Oelze, S. Woelken-Weckmuller, U. Walter, H. Reichenspurner, T. Meinertz, et al. Functional and Biochemical Analysis of Endothelial (Dys)function and NO/cGMP Signaling in Human Blood Vessels With and Without Nitroglycerin Pretreatment Circulation, March 12, 2002; 105(10): 1170 - 1175. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||